Rapidly Progressing Fatal High-Altitude Illness in a Patient with Hyperthyroidism

2018 ◽  
Vol 19 (3) ◽  
pp. 288-290
Author(s):  
Sang Jae Noh ◽  
Ho Lee
2004 ◽  
Vol 22 (2) ◽  
pp. 329-355 ◽  
Author(s):  
Scott A Gallagher ◽  
Peter H Hackett

Author(s):  
Flavia Wipplinger ◽  
Niels Holthof ◽  
Jasmin Lienert ◽  
Anastasia Budowski ◽  
Monika Brodmann Maeder ◽  
...  

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jean-Paul Richalet ◽  
Fabien Pillard ◽  
David Le Moal ◽  
Daniel Rivière ◽  
Philippe Oriol ◽  
...  

Author(s):  
Ajeya Jha ◽  
Ajay Dheer ◽  
Vijay Kumar Mehta ◽  
Saibal Kumar Saha

The adverse health effects of high altitude are of considerable importance since they may seriously interfere with working efficiency of an organization that is actively involved with inescapable duties. The objective of the current study is to explore inter-relational dynamics of various HR aspects in HAIA. The HR aspects included are job delay, poor team, motivation, less leave, high working hours, poor decision making, personal stress, family stress, personal discomfort, uncertainty, poor relations, health, accidents, quality and performance. A decision-making trial and an evaluation laboratory have been used to explore the inter-relation dynamics of various factors of HR. The results indicate that personal stress has the highest impact priority which is followed by poor performance, poor team and motivation. Uncertainty, less leave, and high working hours has the least impact priority. It is also found that high working hours, less leave and poor health are the major causes whereas decrease in motivation and poor quality of work are the major results.


2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Alfredo Merino-Luna ◽  
Julio Vizcarra-Anaya

Acute high-altitude pulmonary edema (HAPE) is a pathology involving multifactorial triggers that are associated with ascents to altitudes over 2,500 meters above sea level (m). Here, we report two pediatric cases of reentry HAPE, from the city of Huaraz, Peru, located at 3,052 m. The characteristics of both cases were similar, wherein acclimatization to sea level and a subsequent return to the city of origin occurred, and we speculate that it was caused by activation of predisposing factors to HAPE. The diagnosis and management associated with pulmonary hypertension became a determining factor for therapy.


2018 ◽  
Vol 8 (1) ◽  
pp. 83-97 ◽  
Author(s):  
Robert A. Kurtzman ◽  
James L. Caruso

High altitude illness (HAI) is the current accepted clinical term for a group of disorders including acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE), which occur in travelers visiting high-altitude locations. High-altitude illness is due to hypobaric hypoxia, is not associated with age or physical conditioning, and mild forms are easily treated. High-altitude cerebral edema and HAPE are medical emergencies that are fatal if not promptly treated and fortunately are uncommon. The cause of most high-altitude fatalities is not related to HAI and can be easily distinguished from HACE and HAPE; however, other causes of death may have symptoms and physical findings that overlap with HAI, making postmortem diagnosis challenging. Fatalities due to HAPE and HACE are diagnoses of exclusion. Medical examiners and coroners who work in jurisdictions with high-altitude locations should be aware of the risk factors, physiology, pathology, differential diagnosis, and classification of HAI to accurately recognize HAI as a cause of death. Medical examiners who do not work in jurisdictions with high-altitude locations may be asked to evaluate deaths that occur overseas associated with high-altitude trekking and mountaineering activities.


Author(s):  
Patrick Levy ◽  
Hugo Nespoulet ◽  
Bernard Wuyam ◽  
Renaud Tamisier ◽  
Claire Saunier ◽  
...  

2001 ◽  
Vol 58 (6) ◽  
pp. 387-393 ◽  
Author(s):  
M. Maggiorini

Jeder zweite Trecker oder Bergsteiger, der rasch (> 300 m/Tag) auf Höhen über 4000 m steigt, hat nach 6 bis 12 Stunden Symptome der Höhenkrankheit. Wir unterscheiden zwei Formen der Höhenkrankheit: die akute Bergkrankheit und das Höhenlungenödem. Die milde und benigne Form der akuten Bergkrankheit äußert sich mit Kopfschmerzen, Appetitlosigkeit, Übelkeit, seltener mit Erbrechen, Schwindelgefühl und Schlaflosigkeit. Die schwere und maligne Form der akuten Bergkrankheit wird Höhenhirnödem genannt und präsentiert sich mit den Symptomen der milden akuten Bergkrankheit mit einer zusätzlichen Gangataxie bis zur Stehunfähigkeit und/oder einer Beeinträchtigung des Bewusstseins bis zum Koma. Die Ursache der akuten Bergkrankheit ist eine zerebrale Dysfunktion, die pathophysiologischen Mechanismen bleiben aber unklar. Das Höhenlungenödem gehört zur Höhenkrankheit, unterscheidet sich aber pathophysiologisch von der akuten Bergkrankheit. Das Höhenlungenödem präsentiert sich klinisch mit stark eingeschränkter Leistungsfähigkeit und Müdigkeit, retrosternalem Druckgefühl, Atemnot, Orthopnoe, Husten, Rasseln in den Atemwegen und blutig tingiertem Auswurf. Pathognomonisch für das Höhenlungen-ödem ist eine Hypoxie-induzierte schwere pulmonal-arterielle Hypertonie. Zweidrittel der Patienten mit Höhenlungenödem hat wegen der schweren Hypoxämie Symptome der malignen akuten Bergkrankheit. Die Behandlung der Höhenkrankheit besteht primär in der Beseitigung der Hypoxie. Acetazolamid (Diamox®), ein Karboanhydrasehemmer, stimuliert die Ventilation und eliminiert die für die Höhe charakteristische periodische Atmung, es eignet sich gut für die Prophylaxe und Behandlung der benignen akuten Bergkrankheit. Die schwere akute Bergkrankheit wird mit Dexamethason (Decadron®) behandelt. Nifedipin (Adalat®), ein wirksamer pulmonaler Vasodilatator, ist das Medikament erster Wahl zur Prophylaxe und Behandlung des Höhenlungenödems.


Sign in / Sign up

Export Citation Format

Share Document